JP5924742B2 - インフラマソームの活性を抑える薬剤をスクリーニングする方法 - Google Patents

インフラマソームの活性を抑える薬剤をスクリーニングする方法 Download PDF

Info

Publication number
JP5924742B2
JP5924742B2 JP2013523401A JP2013523401A JP5924742B2 JP 5924742 B2 JP5924742 B2 JP 5924742B2 JP 2013523401 A JP2013523401 A JP 2013523401A JP 2013523401 A JP2013523401 A JP 2013523401A JP 5924742 B2 JP5924742 B2 JP 5924742B2
Authority
JP
Japan
Prior art keywords
macrophages
nlrp3
derived
lps
test substance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013523401A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013544349A5 (enExample
JP2013544349A (ja
Inventor
中畑　龍俊
龍俊 中畑
斎藤　潤
潤 斎藤
田中　孝之
孝之 田中
伸弥 山中
伸弥 山中
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyoto University NUC
Original Assignee
Kyoto University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyoto University NUC filed Critical Kyoto University NUC
Publication of JP2013544349A publication Critical patent/JP2013544349A/ja
Publication of JP2013544349A5 publication Critical patent/JP2013544349A5/ja
Application granted granted Critical
Publication of JP5924742B2 publication Critical patent/JP5924742B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/5055—Cells of the immune system involving macrophages
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/545—IL-1
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Transplantation (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2013523401A 2010-11-18 2011-11-17 インフラマソームの活性を抑える薬剤をスクリーニングする方法 Expired - Fee Related JP5924742B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41510210P 2010-11-18 2010-11-18
US61/415,102 2010-11-18
PCT/JP2011/077265 WO2012067265A1 (en) 2010-11-18 2011-11-17 Method for screening drugs for suppressing inflammasome activity

Publications (3)

Publication Number Publication Date
JP2013544349A JP2013544349A (ja) 2013-12-12
JP2013544349A5 JP2013544349A5 (enExample) 2015-01-08
JP5924742B2 true JP5924742B2 (ja) 2016-05-25

Family

ID=46084180

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013523401A Expired - Fee Related JP5924742B2 (ja) 2010-11-18 2011-11-17 インフラマソームの活性を抑える薬剤をスクリーニングする方法

Country Status (4)

Country Link
US (1) US9557321B2 (enExample)
EP (1) EP2641086B9 (enExample)
JP (1) JP5924742B2 (enExample)
WO (1) WO2012067265A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103667195B (zh) * 2013-12-17 2016-04-27 南京大学 以nlrp3为靶点的药物筛选细胞模型及其应用
WO2015131076A1 (en) * 2014-02-27 2015-09-03 Yale University Nlrp6 inflammasome intestinal epithelium mucus secretion
JP6445802B2 (ja) * 2014-07-16 2018-12-26 学校法人慶應義塾 インフラマソーム活性化制御物質のスクリーニング方法
PE20221627A1 (es) * 2015-02-16 2022-10-19 Univ Queensland Sulfonilureas y compuestos relacionados y uso de estos
KR101731303B1 (ko) * 2015-06-11 2017-05-02 가톨릭대학교 산학협력단 인터루킨―1베타 억제제의 스크리닝 방법
PT3661925T (pt) 2017-07-07 2022-01-31 Inflazome Ltd Novos compostos de sulfonamida-carboxamida
CN108588209A (zh) * 2018-04-10 2018-09-28 广州中医药大学(广州中医药研究院) 一种用于诊断心血管疾病的分子标志物Nlrp3及其应用
EP3859331A1 (en) 2020-01-31 2021-08-04 Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) Methods for assigning a phenotypic signature for diagnostic and therapeutic applications

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080008652A1 (en) * 2006-01-10 2008-01-10 The Regents Of The University Of Michigan Methods and compositions for mediation of immune responses and adjuvant activity
US20110262956A1 (en) 2008-10-07 2011-10-27 Guillermo Munoz Elias Co-culture compositions and methods
JP2011121949A (ja) * 2009-12-14 2011-06-23 Kyoto Univ 筋萎縮性側索硬化症の予防および治療用医薬組成物

Also Published As

Publication number Publication date
EP2641086A1 (en) 2013-09-25
US9557321B2 (en) 2017-01-31
WO2012067265A1 (en) 2012-05-24
EP2641086A4 (en) 2014-05-14
US20130273588A1 (en) 2013-10-17
JP2013544349A (ja) 2013-12-12
EP2641086B9 (en) 2017-08-16
EP2641086B1 (en) 2017-01-04

Similar Documents

Publication Publication Date Title
JP5924742B2 (ja) インフラマソームの活性を抑える薬剤をスクリーニングする方法
JP6745498B2 (ja) 神経分化誘導用の多能性幹細胞
JP6021021B2 (ja) 多発性嚢胞腎の検査方法および治療剤のスクリーニング方法
JP6153232B2 (ja) 筋萎縮性側索硬化症の予防および治療薬とそのスクリーニング方法
EP2582795B1 (en) Method for selecting human induced pluripotent stem cells
US9074188B2 (en) Cardiomyocyte- and/or cardiac progenitor cell-proliferating agent and method for proliferating cardiomyocytes and/or cardiac progenitor cells
JP5995237B2 (ja) 多能性幹細胞からの好酸球の製造方法
EP3219808B1 (en) Screening method using induced neurons
JPWO2016076435A6 (ja) 誘導神経細胞を用いたスクリーニング方法
JP6436491B2 (ja) 骨髄異形成症候群等の治療／予防薬のスクリーニング方法
KR20180055901A (ko) 간 기능장애의 확인 및 개선에 기반한 파킨슨병의 진단 및 치료
JP6621195B2 (ja) 多発性嚢胞腎の検査方法および治療剤のスクリーニング方法
JP7030343B2 (ja) 疾患ｉＰＳ細胞を用いた神経毒性評価モデル系及びその使用
JPWO2018225751A1 (ja) 大腸がん幹細胞の維持増幅方法、及び大腸がんオルガノイドの誘導方法
JP7671987B2 (ja) 繊毛関連疾患モデルおよびその利用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141114

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141114

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160118

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160315

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160413

R150 Certificate of patent or registration of utility model

Ref document number: 5924742

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees